- Home
- JLL vs SNN Comparison
JLL vs SNN Comparison
Compare JLL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | SNN |
|---|---|---|
| Founded | 1997 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.0B |
| IPO Year | 1997 | 1999 |
Fundamental Metrics
Financial Performance| Metric | JLL | SNN |
|---|---|---|
| Price | $327.48 | $33.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $342.14 | $32.83 |
| AVG Volume (30 Days) | 306.0K | ★ 476.9K |
| Earning Date | 11-05-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | 31.91 | ★ 59.91 |
| EPS | ★ 13.05 | 0.56 |
| Revenue | ★ $25,317,800,000.00 | $5,944,000,000.00 |
| Revenue This Year | $11.77 | $7.78 |
| Revenue Next Year | $7.01 | $5.13 |
| P/E Ratio | ★ $25.11 | $29.10 |
| Revenue Growth | ★ 12.51 | 5.35 |
| 52 Week Low | $194.36 | $23.69 |
| 52 Week High | $335.83 | $38.79 |
Technical Indicators
Market Signals| Indicator | JLL | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 48.01 |
| Support Level | $319.74 | $32.68 |
| Resistance Level | $332.02 | $33.56 |
| Average True Range (ATR) | 9.52 | 0.41 |
| MACD | 1.62 | 0.14 |
| Stochastic Oscillator | 81.20 | 78.51 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.